Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy

Lung Cancer, 04/27/2012

Survival was significantly better for patients with good PS than poor performance status and those with, than without grade IV tumor staining. If a sufficient number of feeding arteries are detected and the tumor is appropriately stained, then arterial infusion chemotherapy has favorable response rates with less toxicity for patients with stage III or IV or recurrent non–small–cell lung cancer without distant metastasis who cannot tolerate standard chemotherapy.

Print Article Summary Cat 2 CME Report